Identification of patients who could benefit from bedaquiline or delamanid: A multisite MDR-TB cohort study

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 2, 2016, Pages 177-186

  Bonnet, M ^a,b   Bastard, M ^a   Du Cros, P ^c   Khamraev, A ^d   Kimenye, K ^e   Khurkhumal, S ^f   Hayrapetyan, A ^g   Themba, D ^h   Telnov, A ⁱ   Sanchez Padilla, E ^a   Hewison, C ^j   Varaine, F ^j  

^a EPICENTRE   (France)

^b INSERM   (France)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d Ministry of Health of Karakalpakstan   (Uzbekistan)

^e Division of Leprosy Tuberculosis and Lung Disease   (Kenya)

^f Abkhazian National Tuberculosis Programme   (Georgia)

^g Armenian National Tuberculosis Programme   (Armenia)

^h Swaziland Ministry of Health   (Swaziland)

ⁱ MSF   (Switzerland)

^j MSF   (France)

more..

Author keywords

Drug resistance; Outcomes; Regimens; Resource limited; Treatment; Tuberculosis

Indexed keywords

BEDAQUILINE; CAPREOMYCIN; DELAMANID; KANAMYCIN; OFLOXACIN; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ARMENIA; ARTICLE; BACTERIAL LOAD; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; FEMALE; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SWAZILAND; UNITED STATES; UZBEKISTAN; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; PATIENT SELECTION; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; USSR; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; DIARYLQUINOLINES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KENYA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; ODDS RATIO; OXAZOLES; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK FACTORS; SWAZILAND; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; USSR; YOUNG ADULT;

EID: 84954461181     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0962     Document Type: Article

References (27)

1. World Health Organization. Global tuberculosis report, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
2. Sanchez-Padilla E., Dlamini T, Ascorra A., et al. High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010. Emerg Infect Dis 2012; 18: 29-37.
3. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011. http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583-eng.pdf Accessed November 2015.
4. Orenstein E.W., Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
5. Johnston J.C., Shahidi N C, Sadatsafavi M, FitzGerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLOS ONE 2009; 4: e6914.
6. Ahuja S.D., Ashkin D, Avendano M., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLOS MED 2012; 9: e1001300.
7. Bastos M.L., Hussain H, Weyer K., et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first-and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014; 59: 1364-1374.
8. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, Switzerland: WHO, 2014. http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809-eng.pdf?ua=1&ua=1 Accessed October 2015.
9. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB2014.23. Geneva, Switzerland: WHO, 2014.
10. World Health Organization. Interim guidance on the use of bedaquilinetotreat MDR-TB. WHO/HTM/TB/2013.6. Geneva, Switzerland: WHO, 2014. http://www.who.int/tb/challenges/mdr/bedaquiline/en/index.html Accessed October 2015.
11. Ulmasova D.J., Uzakova G, Tillyashayhov M N, et al. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011. Euro Surveill 2013; 18. pii: 20609.
12. Pardini M, Niemann S, Varaine F., et al. Characteristics of drugresistant tuberculosis in Abkhazia (Georgia), a high-prevalence area in Eastern Europe. Tuberculosis (Edinb) 2009; 89: 317-324.
13. Bonnet M, Pardini M, Meacci F., et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLOS ONE 2011; 6: e23081.
14. World Health Organization. Management of MDR-TB: a field guide. WHO/HTM/TB/2008.402a Geneva, Switzerland: WHO, 2008. http://www.who.int/tb/publications/2008/tb-field-guide-9789241547765/en/index.html Accessed October 2015.
15. Cox H.S., Sibilia K, Feuerriegel S., et al. Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis. N Engl J Med 2008; 359: 2398-2400.
16. Cegielski J.P., Dalton T, Yagui M., et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59: 1049-1063.
17. Sanchez-Padilla E., Marquer C, Kalon S., et al. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study. Int J Tuberc Lung Dis 2014; 18: 160-167.
18. Falzon D, Gandhi N, Migliori G B, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
19. Kurbatova E.V., Taylor A, Gammino V M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb) 2012; 92: 397-403.
20. Van Deun A., Maug A K J Salim M A H, et al. Short, highly effective, and inexpensive standardized treatment of multidrugresistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
21. Caminero J.A., Sotgiu G, Zumla A., Migliori G B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
22. Monedero I, Caminero J A. Management of multidrug-resistant tuberculosis: an update. Ther Adv Respir Dis 2010; 4: 117-127.
23. Franke M.F., Becerra M C, Tierney D B, et al. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis. Ann Am Thorac Soc 2015; 12: 674-679.
24. World Health Organization. Policy guidance on drugsusceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392. Geneva, Switzerland: WHO, 2008. http://www.who.int/tb/publications/2008/whohtmtb-2008-392/en/ Accessed October 2015.
25. World Health Organization. An initiative to extend access to a new TB drug. Geneva, Switzerland: WHO, 2015. http://www.who.int/tb/features-archive/otsuka-2015/en/ Accessed October 2015.
26. nd ed. Geneva, Switzerland: MSF, 2012. msfaccess.org. http://www.msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition. Accessed October 2015.
27. Migliori G.B., Sotgiu G, Gandhi N R, et al. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2012; 42: 169-179.